ESMO – European Society for Medical Oncology posted on LinkedIn:
“ADCs present a promising therapeutic option, however the expression patterns of key ADC targets remain unclear.
This study presented at ESMO Gynae25 evaluated the expression of five ADC targets to assess their potential utility in Ovarian Cancer.
Findings reveal targetable alterations, that could lead to better therapeutic options and improved patient outcomes.”
Read Further: 20 Posts Not to Miss from ESMO Gynaecological Cancers Congress 2025.